MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases

Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695

eTOC

Minerva Cardioangiologica 2018 Mar 28

DOI: 10.23736/S0026-4725.18.04659-5

Copyright © 2018 EDIZIONI MINERVA MEDICA

language: English

A review of percutaneous tricuspid valve replacement: orthotopic and heterotopic valves

Kimberly ATIANZAR ¹, Ming ZHANG ¹, Sameer GAFOOR ^{1, 2} ✉

¹ Swedish Heart and Vascular Institute, Seattle, WA; ² Cardiovascular Center Frankfurt, Frankfurt, Germany

PDF  

The tricuspid valve has long been described as the “forgotten valve”, leaving tricuspid valve disease relatively neglected. However, the number of people in the United States affected by severe tricuspid regurgitation is growing. Isolated surgery for severe tricuspid regurgitation in the setting of right ventricular heart failure carries a high mortality risk, and therefore, attention to corrective therapies has increased. Because of the different etiologies for tricuspid regurgitation, multiple percutaneous transcatheter options for tricuspid valve repair for severe regurgitation are being studied and have been developed, including annuloplasty systems, leaflet and coaptation devices, vena caval (heterotopic) valve implantations, and tricuspid valve (orthotopic) replacement. In this paper, we review the heterotopic and orthotopic tricuspid valve transcatheter options for severe tricuspid regurgitation.

KEY WORDS: Tricuspid valve regurgitation - Percutaneous transcatheter valve replacement - Heterotopic tricuspid valve transcatheter options - Orthotopic tricuspid valve transcatheter options